AU699677B2 - Surfactant free aerosol formulations containing beclomathasone dipropionate - Google Patents

Surfactant free aerosol formulations containing beclomathasone dipropionate Download PDF

Info

Publication number
AU699677B2
AU699677B2 AU70363/96A AU7036396A AU699677B2 AU 699677 B2 AU699677 B2 AU 699677B2 AU 70363/96 A AU70363/96 A AU 70363/96A AU 7036396 A AU7036396 A AU 7036396A AU 699677 B2 AU699677 B2 AU 699677B2
Authority
AU
Australia
Prior art keywords
formulation
beclomethasone dipropionate
propellant
dipropionate
pharmaceutical aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU70363/96A
Other versions
AU7036396A (en
Inventor
Philip John Neale
Anthony James Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB929216381A priority Critical patent/GB9216381D0/en
Priority to GB929216382A priority patent/GB9216382D0/en
Priority to GB9216382 priority
Priority to GB9216381 priority
Priority to AU47050/93A priority patent/AU670616B2/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU7036396A publication Critical patent/AU7036396A/en
Application granted granted Critical
Publication of AU699677B2 publication Critical patent/AU699677B2/en
Anticipated expiration legal-status Critical
Application status is Ceased legal-status Critical

Links

Description

I -lyL. J I_ Regulation 3.2

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

(ORIGINAL)

e oo

I

t to 0 o., P o *c 0 o

*W

Name of Applicant: Glaxo Group Limited Actual Inventor(s): Anthony James Taylor Philip John Neale Address for Service: DAVIES COLLISON CAVE, Patent Attorneys, 1 Little Collins Street, Melbourne, 3000.

Invention Title: Surfactant free aerosol formulations containing beclomethasone dipropionate The following statement is a full description of this invention, including the best method of performing it known to me/us: -1- P:\OPER\RMH\GLAXO.SPE- 815/97 13- 1A

MEDICAMENTS

This invention relates to novel aerosol formulations for administering drugs, in particular for administration of a beclomethasone ester by inhalation.

Beclomethasone dipropionate is 9a-chloro-16B-methyl-1,4-pregnadiene-11B, 17a,21-triol-3,20-dione 17a,21-dipropionate and may be represented by the formula (I) 0II

CH

20 C C 2 H, CH OH CH 3

.OCCH

2

CH

3 CH C3 H 0. 1 c. Ij l

H

The corticosteroid of formula is known to exhibit topical antiinflammatory activity and is useful in the treatment of asthmatic conditions, particularly in the form of aerosol formulations. The use of such formulations is described in GB- 1429184 where it is noted that micronised anhydrous beclomethasone dipropionate tends to display crystal growth, due to solvate formation, when incorporated into aerosol formulations containing chlorofluorocarbon propellants. Crystals having a particle size of more than 20 microns were 15 shown to be too large to penetrate the bronchial system and prone to cause clogging of the metering valve making them unsuitable for administration by inhalation.

A number of potential solutions to this problem have been proposed. These include the use of micronised solvates of beclomethasone dipropionate, for example chlorofluorocarbon solvates (GB-1429184), ethyl acetate solvate (DE- 30185500S), C5_8alkane solvates (EP-0039369), diisopropyl ether solvate (EP- 2i 0172672) and C1- 5 alcohol solvates (W086/03750). GB-2076422A discloses a process for the preparation of chlorofluorocarbon aerosols which incorporates a low temperature (5 to -40 0 C) step which is also claimed to inhibit crystal growth.

An alternative solution to the problem of crystal growth in aerosol formulations containing beclomethasone dipropionate has recently been disclosed in W092/06675. This document describes the preparation of aerosol formulations containing solutions of beclomethasone diproprionate in ethanol, together with hydrofluorocarbon 134a (1,1,1,2-tetrafluoroethane) or hydrofluorocarbon 227 (1,1,1,2,3,3,3-heptafluoropropane) as propellant. Since a solution of beclomethasone dipropionate in ethanol is employed in the aerosols rather than a suspension of particulate beclomethasone diproprionate, elaborate process steps or the preparation of a solvate of the active ingredient prior to incorporation into the aerosol formulation is not required.

Nevertheless, whilst ethanol is pharmaceutically acceptable and generally recognised as safe, it is associated with a number of disadvantages which may restrict is use. In particular, administration of ethanol-containing products to teetotal or alcohol-dependent individuals or to children is undesirable.

A number of other patent applications describe the preparation of aerosol formulations containing drug and a fluorocarbon propellant, together with the 20 addition of one or more adjuvants such as surfactants. Thus, for example W091/14422 describes the preparation of aerosol formulations containing beclomethasone dipropionate in the form of its 1,1,1,2-tetrafluoroethane -clathrate together with 1,1,1,2-tetrafluoroethane and various surface-active dispersing agents.

,i 25 We have now found that certain novel aerosol formulations containing particulate beclomethasone diproprionate are surprisingly stable without recourse to the use of any adjuvant or cosolvent in the composition.

t: 9 17 P:\OPERRMHlGLAXO.SP -30/9/96 -3- According to an aspect of the present invention there is provided a pharmaceutical aerosol formulation which comprises particulate anhydrous beclomethasone dipropionate together with a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. By "substantially free of surfactant" is meant formulations which contain no significant amounts of surfactant, for example less than 0.0001 by weight of the beclomethasone dipropionate.

A particularly preferred embodiment of the invention provides a pharmaceutical aerosol formulation which consists essentially of anhydrous beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant.

The particle size of the particulate beclomethasone dipropionate may be reduced by conventional methods, for example by micronisation, fluid energy milling or ball milling and should be such as to permit inhalation of substantially all of the drug into the lungs upon administration of the aerosol formulation. Preferably the particle size of the beclomethasone dipropionate will be less than 20 microns, most preferably less than 10 microns, in particular in the range of 1 to 5 microns.

Alternatively, the beclomethasone dipropionate may be employed in solvate form in 20 compositions according to the invention. Suitable pharmaceutically acceptable solvates of beclomethasone dipropionate include solvates with chlorofluorocarbons, ethyl acetate, ,I alkanes, ethers, alcohols and water. However, beclomethasone dipropionate is preferably used in the form of a solvate with 1,1,1,2-tetrafluoroethane (CF 3

CH

2

F).

25 According to another aspect of the present invention there is provided a pharmaceutical aerosol formulation which comprises particulate beclomethasone dipropionate-1,1,1,2tetrafluoroethane solvate together with a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant.

The term "beclomethasone dipropionate-1,1,1,2-tetrafluoroethane solvate" as used herein P\OPER\RMH\GLAXO.SPE 30/9/96 i refers to any crystalline material in which beclomethasone dipropionate and 1,1,1,2tetrafluoroethane are associated. The ratio of the steroid to the solvating species need not be stoichiometric and no particular mechanism of association is implied. The solvate may contain, for example from about 20 to about 30% by weight of 1,1,1,2-tetrafluoroethane, the precise amount depending on the particular method of preparation used.

Preferably the solvate is prepared by intimate admixture of beclomethasone dipropionate with 1,1,1,2-tetrafluoroethane to form a crystalline solvate therewith. The process is desirably carried out in the absence of other potential solvating species such as water, alcohol, chlorofluorocarbons, ethyl acetate, alkane and diisopropyl ether. Thus, for example, micronised beclomethasone dipropionate may be contacted with dry, preferably liquified, 1,1,1,2-tetrafluoroethane. The crystalline solvate formed can be obtained by conventional means such as filtration and drying.

We have found that the beclomethasone dipropionate-l,1,1,2-tetrafluoroethane solvate is surprisingly stable at ambient temperatures and pressures. In particular, beclomethasone Sl dipropionate-l,1,1,2-tetrafluoroethane solvate has been found to be stable at temperatures up to about 65"C. The particle size of the crystalline solvate may be reduced by conventional methods, for example by micronisation, fluid energy milling or ball milling and should be such 20 as to permit inhalation of substantially all of the medicament into the lungs. Preferably the particle size of the solvate is reduced in an atmosphere or partial atmosphere of 1, 1, 1,2-tetrafluoroethane. The solvate in micronised form may be incorporated into aerosol formulations and unexpectedly does not exhibit any significant crystal growth or agglomeration.

Furthermore, the solvate appears to be more easily wetted than the anhydrous or other known 25 solvates ofbeclomethasone dipropionate in 1,1,1,2-tetrafluoroethane enabling the preparation of aerosols with improved dispersion characteristics.

The propellants for use in the invention may be any fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof having a sufficient vapour pressure to render them effective as propellants. Preferably the propellantwill be a non-solvent for the medicament.

I_

1; p:OPERR I -*t fa\ILAXO.Spi'0/ 9 96 -4A- Suitable propellants include for example

C_

4 hydrogen-Containing chlorofluorocarbons such as CH 2 CIF, CCIF 2 CHCJ±,

CF

3 CHCIFI

CHF

2

CCIF

2 CHCIFCJT2,

CF

3

CH

2 GI and CCIF 2

CH

3

C,

4 hydrogen-containing fluorocarbons such as CHF 2

CEF

2

CF

3

CH

2 F, CHF 2

CH

3 and

CF

3 CI{FCF 3 and C 1 perfluorocarbons such as CF 3

CF

3 and CF 3

CF

2

CF

3 Li a

**CC

a 0 C o~ Where mixtures of the fluorocarbons or hydrogen-containing chlorofluorocarbons are employed they may be mixtures of the above identified compounds or mixtures, preferably binary mixtures, with other fluorocarbons or hydrogen-containing chlorofluorocarbons for example CHCIF 2

CH

2

F

2 and

CF

3

CH

3 Preferably a single fluorocarbon or hydrogen-containing chlorofluorocarbon is employed as the propellant. Particularly preferred as propellants are hydrogencontaining fluorocarbons, especially 1,1,1,2-tetrafluoroethane (CF 3

CH

2 F) and 1,1,1,2,3,3,3-heptafluoro-n-propane (CF 3

CHFCF

3 It is desirable that the formulations of the invention contain no components which may provoke the degradation of stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarbons especially non hydrogen-containing chlorofluorocarbons such as CCI 3

F,

CCI

2

F

2 and CF 3

CCI

3 As used herein "substantially free" means less than 1% 1 5 w/w based upon the fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, in particular less than for example 0.1% or less.

The propellant may optionally contain an adjuvant having a higher polarity and/or a higher boiling point than the propellant. Polar adjuvants which may be used include C2-6) aliphatic alcohols and polyols such as ethanol, isopropanol and propylene glycol, preferably ethanol. In general only small quantities of polar adjuvants 0.05 3.0% w/w) are required to improve the stability of the dispersion the use of quantities in excess of 5% w/w may tend to dissolve the medicament. Formulations in accordance with the invention *preferably contain less than 1% w/w, e.g. about 0.1% w/w or less, of polar adjuvants. Suitable volatile adjuvants include saturated hydrocarbons such as o propane, n-butane, isobutane, pentane and isopentane and alkyl ethers such as S dimethyl ether. In general, up to 50% w/w of the propellant may comprise a volatile adjuvant, for example 1 to 30% w/w of a volatile saturated C1-6 hydrocarbon.

I I~ i P;\OPERRMH\GLAXO.SPE- 30/9/96 -6- However, it is preferable that the formulations of the invention are substantially free of other potential solvating species such as chlorofluorocarbons, ethyl acetate, alkanes, ethers, alcohols I and water. In particular, the formulations are substantially free of water, for example containing less than 250ppm, preferably less than 200ppm, more preferably less than 100ppm, for example less than 50ppm water.

1 A particularly preferred embodiment of the invention provides a pharmaceutical aerosol formulation which consists essentially of beclomethasone dipropionate-1,1,1,2i tetrafluoroethane solvate and one or more fluorocarbon or hydrogen-containing S 10 chlorofluorocarbon propellants, particularly 1,1,1 ,2-tetrafluoroethane.

The final aerosol formulation desirably contains 0.005-10% w/w, preferably 0.005-5.0% w/w, especially 0.01-1.0% w/w, for example 0.01-0.5% w/w of beclomethasone dipropionate relative to the total weight of the formulation.

It will be appreciated by those skilled in the art that the aerosol formulations according to the I invention may, if desired, contain one or more additional active ingredients. Aerosol o compositions containing two active ingredients (in a conventional propellant system) are known, for example, for the treatment of respiratory disorders such as asthma. Accordingly the present invention further 7 provides aerosol formulations in accordance with the invention which contain one or more additional particulate medicaments. Additional medicaments may be selected from any other suitable drug useful in inhalation therapy and which may be presented in a form which is substantially completely insoluble in the selected propellant. Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; antiinfectives e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. fluticasone, flunisolide, budesonide, tipredane or triamcinolone acetonide; antitussives, e.g. noscapine; bronchodilators, e.g. salmeterol, salbutamol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline, or (-)-4-amino-3,5-dichloro-c-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol; diuretics, e.g. amiloride; anticholinergics e.g.

ipratropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophyllin3; and therapeutic proteins and peptides, e.g.

20 insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts as alkali metal or amine salts or as acid addition salts) or as esters lower alkyl esters) or as solvates hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the 25 propellant.

Particularly preferred aerosol formulations contain salbutamol as the free base or the sulphate salt) or salmeterol as tIe xinafoate salt) in combination with the beclomethasone diproprionate. Combinations of salmeterol xinafoate and beclomethasone dipropionate are preferred.

The formulations of the invention may be prepared by dispersal of the medicament in the selected propellant in an appropriate container, e.g. with the aid of sonication.

I *5 i ft i! 1 ft r Minimising and preferably avoiding the use of formulation excipients e.g.

surfactants, cosolvents etc in the aerosol formulations according to the invention is advantageous since the formulations may be substantially taste and odour free, less irritant and less toxic than conventional formulations.

The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art. Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.

The formulations according to the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations. Canisters qenerally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene.

Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France DF10, DF30, Bespak plc, UK 8K300, BK356, BK357) and 3M-Neotechnic Ltd, UK (e.g.

SpraymiserTM).

Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large scale batches for the commercial production of filled 1111111~ 1111IICI~II~- ll~ 9 canisters. Thus, for example, in one bulk manufacturing method a, metering valve is crimped onto an aluminium can to form an empty canister. The particulate medicament is added to a cllarge vessel and liquified propellant is pressure filled through the charge vessel into a manufacturing vessel. The drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister.

Typically, in batches prepared for pharmaceutical use, each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing.

Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator. Metered dose inhalers are designed to deliver a fixed init dosage of medicament per actuation or "puff", for example in the range of 10 to 5000 microgram medicament per S puff.

S 0: 9o Administration of medicament may be indicated for the treatment of mild, 20 moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient, the particular particulate medicament used and the frequency of administration and will ultimately be at the discretion of the attendant physician When combinations of medicaments are employed the 25 dose of each component of the combination will in general be that employed for I each component when used alone. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.

Suitable daily doses, may be, for example in the range 100 to 2000 microgram of beclomethasone dipropionate, depending on the severity of the disease.

I Thus, for example, each valve actuation may deliver 50, 100, 200 or 250 microgram beclomethasone dipropionate. Typically each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medk :t.

The fil;-,:I canisters and metered dose inhalers described herein comprise further aspects Of the present invention.

A still further aspect of the present invention comprises a method of treating respiratory disorders such as, for example, asthma, which comprises administration by inhalation of an effective amount of a formulation as herein described.

The following non-limitative Examples serve to illustrate the invention.

Example 1 Beclomethasone dipropionate-1.1.1.2-tetrafluoroethane solvate ,"Micronised anhydrous beclomethasone dipropionate (25.2mg) was weighed into a clean dry plastic-coated glass bottle and dry (<50ppm H 2 0) 1,1,1,2o'"l tetrafluoroethane (to 18.2g) was added from a vacuum flask. The bottle was quickly sealed with a blank aluminium ferrule. The bottle was allowed to stand at ambient temperature. After several days crystals of the solvate formed were isolated by filtration.

L oI 20 The solvate thus obtained was analysed by various techniques.

.4 Microscopic examination of the solvate showed the crystals to be columnar and prismatic and up to 500 to 1000 microns in length.

The solid state infra-red spectrum of the solvate was analysed. The most obvious differences between this spectrum and the solid state infra-red spectrum of anhydrous beclomethasone dipropionate were as follows l-ll-- -slr~ C--l 11 (a)The broad OH band at 3300cm- 1 is raised to near 3500cm- 1 and is sharpened; (b)The carbonyl band at 1750cm- 1 is split into three distinct peaks indicating the solvated form; and (c)The 1,4.diene peaks are more widely separated with the 1610cm- 1 peak moved up to about 1630cm- 1 Other differences were also apparent throughout the whole region examined with most peaks changed in position and intensity after solvation.

Thermogravimetric analysis and differential scanning calorimetry of the solvate at atmospheric pressure was carried out using a Netzsch Simultaneous Thermal Analyser STA409. Loss of 1,1,1,2-tetrafluoroethane started to occur at 650C.

Heat absorption continued to about 900C when an exothermic change resulted from 900 to 110 0 C which corresponded with completion of the loss of 1,1,1,2tetrafluoroethane at 1200C. This profile differs significantly from that of the 15 known beclomethasone dipropionate-trichlorofluoromethane solvate in which trichlorofluoromethane loss starts to occur at 300C.

The thermogravimetric analysis showed a total weight loss of 23.1% on heating the beclomethasone dipropionate-1,1,1,2- tetrafluoroethane solvate indicating a ratio of 3 molecules of 1,1,1,2-tetrafluoroethane to 2 molecules of 20 beclomethasone dipropionate.

Example 2 Bedomethasone dipropionate-1.1.1.2-tetrafluoroethane solvate Micronised anhydrous beclomethasone dipropionate (24.1mg) and lecithin (3.3mg) were weighed into a clean dry plastic-coated glass bottle and dry

H

2 0) 1,1,1,2-tetrafluoroethane (to 18.2g) was added from a vacuum flask. The bottle was quickly sealed with a blank aluminium ferrule. The bottle was allowed to stand at ambient temperature. After several days, the solvate Scrystals were isolated by filtration. The crystal shape, infra-red spectrum and P:\OPER\RMH\GLAXO.SPE 30/9/96 -12- I thermal analysis of the solvate obtained was substantially identical with the solvate of Example 1.

Example 3 Aerosol Formulation Micronised beclomethasone dipropionate-1,1,1,2-tetrafluoroethane solvate, prepared according to Example 1 (31mg), was weighed into a clean, dry, plastic-coated glass bottle and 1dry (<50ppm H 2 0) 1,1,1,2-tetrafluoroethane (18.2g) was added from a vacuum flask. The bottle was quickly sealed with a blank aluminium ferrule. The resulti"g aerosol contained i 10 0.138% beclomethasone dipropionate (0.170% w/w solvate).

SExample 4 :Aerosol Formulation Micronised anhydrous beclomethasone dipropionate (60 mg), was weighed into a "J 15 clean, dry, plastic-oated glass bottle and dry 50ppm H 2 0) 1,1,1,2,3,3,3-heptafluoro-n- 0 propane (18.2g) was added from a vacuum flask. The bottle was quickly sealed with a blank aluminium ferrule. The resulting aerosol contained 0.33% beclomethasone M dipropionate.

I

i 20 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be y understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integer.

Claims (1)

13- IE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: r :1 j C C t C 4 4 q SOSr 1. A pharmaceutical aerosol formulation which comprises particulate anhydrous beclomethasone dipropionate together with a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. 2. A formulation as claimed in claim 1 wherein the propellant is 1,1,1,2,3,3,3- heptafluoro-n-propane. 3. A formulation as claimed in any one of claims 1 to 2 which contains 0.005-5.0% w/w of beclomethasone dipropionate relative to the total weight of the formulation. 4. A formulation as claimed in any one of claims 1 to 3 wherein the particle size of the anhydrous beclomethasone dipropionate is such as to permit inhalation of substantially all of 15 the drug into the lungs upon administration of the acrosol formulation. A formulation as claimed in any one of claims 1 to 4 which additionally contains salbutamol. 20 6. A pharmaceutical aerosol formulation which consists essentially of particulate anhydrous beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant. 7. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation as claimed in any one of claims 1 to 6. 8. A metered dose inhaler which comprises a canister as claimed in claim 7 fitted into a suitable channelling device. Cc C tCt CLI L CCL CI I I t P:OPER\DCD\PILESBY.SEC\GLAXO.SPE- 13/10/98 -14- 9. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as claimed in any one of claims 1 to 6. 5 10. A pharmaceutical aerosol formulation according to any one of claims 1 to 6, a canister according to claim 7, a metered dose inhaler according to claim 8, or methods of treatment according to claim 9, substantially as hereinbefore described. Dated this THIRTEENTH day of OCTOBER 1998 Glaxo Group Limited by its Patent Attorneys DAVIES COLLISON CAVE eo o o 0 o 0*0 00r 00000 000000 0* 0 0t 00 0 a 0 ao soe CO 00 6 0s C Oa 0 oC 00 6 e o a oo eQ 0 0 0 ft 0 9 0 I* t a p ~aR~ P:\OPER\RMH\GLAXO.SPE 30/9/96 ABSTRACT This invention relates to novel aerosol formulations for administering drugs, in particular for administration of a beclomethasone ester by inhalation. In particular the invention provides novel aerosol formulations consisting essentially of particulate anhydrous beclomethasone dipropionate together with a fluorocarbon or hydrogen- containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. 4 0 oa 0 4 0640 S p6 0000 0 o to U*
AU70363/96A 1992-07-31 1996-10-24 Surfactant free aerosol formulations containing beclomathasone dipropionate Ceased AU699677B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB929216381A GB9216381D0 (en) 1992-07-31 1992-07-31 Medicaments
GB929216382A GB9216382D0 (en) 1992-07-31 1992-07-31 Medicaments
GB9216382 1992-07-31
GB9216381 1992-07-31
AU47050/93A AU670616B2 (en) 1992-07-31 1993-07-30 Surfactant free aerosol formulations containing beclomethasone dipropionate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU47050/93A Division AU670616B2 (en) 1992-07-31 1993-07-30 Surfactant free aerosol formulations containing beclomethasone dipropionate

Publications (2)

Publication Number Publication Date
AU7036396A AU7036396A (en) 1997-01-09
AU699677B2 true AU699677B2 (en) 1998-12-10

Family

ID=27154447

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70363/96A Ceased AU699677B2 (en) 1992-07-31 1996-10-24 Surfactant free aerosol formulations containing beclomathasone dipropionate

Country Status (1)

Country Link
AU (1) AU699677B2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017592A (en) * 1991-06-10 1993-01-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
AU2178992A (en) * 1991-06-10 1993-01-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017592A (en) * 1991-06-10 1993-01-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
AU2178992A (en) * 1991-06-10 1993-01-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations

Also Published As

Publication number Publication date
AU7036396A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
EP0653204B1 (en) Medicinal aerosol formulations
AU2002313828B2 (en) Pharmaceutical compositions for the treatment of asthma
CA2338680C (en) Medicinal aerosol formulations
US5776434A (en) Medicinal aerosol formulations
US5674473A (en) Medicinal aerosol formulations
EP1092430B1 (en) Non-chlorofluorocarbon aerosol formulations
US8142763B2 (en) Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
CA2094726C (en) Non-chlorofluorocarbon aerosol formulation comprising a particulate medicament
US8420058B2 (en) Pharmaceutical aerosol composition
ES2199739T3 (en) Aerosol compositions.
CN1088580C (en) Aerosol drug formulations
US6346232B1 (en) Method of forming conductive lines
EP0536250B1 (en) Aerosol drug formulations
CA2411047C (en) Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US6644306B1 (en) Valve for aerosol container
EP0536204B1 (en) The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
CN100496608C (en) Medical aerosol formulations
ES2242822T3 (en) Antibody for use in therapy.
EP0920302B1 (en) Pharmaceutical aerosol composition
EP1069887B1 (en) Aerosol composition
EP1133277B1 (en) Pharmaceutical aerosol composition containing hfa 227 and hfa 134a
US6613307B1 (en) Aerosol formulations of salmeterol xinafoate
DK0918507T4 (en) aerosol
EP1248597B1 (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
AP742A (en) Pharmaceutical aerosol formualtions containing fluorinated surfactants.